[CLS] O
Selegiline B
- O
induced O
postural O
hypotension O
in O
Parkinson O
' O
s O
disease O
: O
a O
longitudinal O
study O
on O
the O
effects O
of O
drug O
withdrawal O
. O
[SEP] O

[CLS] O
CONCLUSION O
: O
This O
study O
confirms O
our O
previous O
finding O
that O
selegiline B
in O
combination O
with O
L B
- I
dopa I
is O
associated O
with O
selective O
orthostatic O
hypotension O
. O
[SEP] O

[CLS] O
In O
the O
in O
vivo O
study O
, O
the O
administration O
( O
50 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
of O
TET B
and O
FAN B
in O
mice O
showed O
the O
inhibition O
of O
thrombosis O
by O
55 O
% O
and O
35 O
% O
, O
respectively O
, O
while O
acetylsalicylic B
acid I
( O
ASA B
, O
50 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
, O
a O
positive O
control O
, O
showed O
only O
30 O
% O
inhibition O
. O
[SEP] O

[CLS] O
The O
haemodynamic O
effects O
of O
propofol B
in O
combination O
with O
ephedrine B
in O
elderly O
patients O
( O
ASA O
groups O
3 O
and O
4 O
) O
. O
[SEP] O

[CLS] O
Recent O
reports O
indicate O
that O
single O
agent O
therapy O
with O
vinorelbine B
( O
VNB B
) O
or O
gemcitabine B
( O
GEM B
) O
may O
obtain O
a O
response O
rate O
of O
20 O
- O
30 O
% O
in O
elderly O
patients O
, O
with O
acceptable O
toxicity O
and O
improvement O
in O
symptoms O
and O
quality O
of O
life O
. O
[SEP] O

[CLS] O
A O
selective O
dopamine B
D4 O
receptor O
antagonist O
, O
NRA0160 B
: O
a O
preclinical O
neuropharmacological O
profile O
. O
[SEP] O

[CLS] O
Warfarin B
- O
induced O
artery O
calcification O
is O
accelerated O
by O
growth O
and O
vitamin B
D I
. O
[SEP] O

[CLS] O
High O
doses O
of O
vitamin B
D I
are O
known O
to O
cause O
calcification O
of O
the O
artery O
media O
in O
as O
little O
as O
3 O
to O
4 O
days O
. O
[SEP] O

[CLS] O
From O
such O
experiments O
there O
is O
evidence O
that O
characterization O
and O
detection O
of O
apomorphine B
- O
induced O
activity O
in O
rodents O
critically O
depends O
upon O
the O
test O
conditions O
employed O
. O
[SEP] O

[CLS] O
Tamoxifen B
( O
TAM B
) O
, O
the O
antiestrogenic O
drug O
most O
widely O
prescribed O
in O
the O
chemotherapy O
of O
breast O
cancer O
, O
induces O
changes O
in O
normal O
discoid O
shape O
of O
erythrocytes O
and O
hemolytic O
anemia O
. O
[SEP] O

[CLS] O
Either O
alpha B
- I
T I
or O
alpha B
- I
TAc I
increases O
membrane O
packing O
and O
prevents O
TAM B
partition O
into O
model O
membranes O
. O
[SEP] O

[CLS] O
After O
4 O
- O
week O
administration O
of O
L B
- I
NAME I
, O
the O
systolic O
blood O
pressure O
( O
SBP O
) O
increased O
by O
36 O
% O
. O
[SEP] O

[CLS] O
This O
study O
was O
conducted O
to O
examine O
whether O
prolonged O
pretreatment O
with O
isoproterenol B
could O
abolish O
bromocriptine B
- O
induced O
tachycardia O
in O
conscious O
rats O
. O
[SEP] O

[CLS] O
Previous O
investigations O
have O
determined O
that O
, O
in O
response O
to O
clonidine B
, O
ultrasound O
production O
increases O
through O
the O
2nd O
- O
week O
postpartum O
and O
decreases O
thereafter O
. O
[SEP] O

[CLS] O
The O
adjusted O
rate O
ratio O
of O
VTE O
for O
repeat O
users O
of O
third O
generation O
OC B
was O
0 O
. O
6 O
( O
95 O
% O
CI O
: O
0 O
. O
3 O
- O
1 O
. O
2 O
) O
relative O
to O
repeat O
users O
of O
second O
generation O
pills O
, O
whereas O
it O
was O
1 O
. O
3 O
( O
95 O
% O
CI O
: O
0 O
. O
7 O
- O
2 O
. O
4 O
) O
for O
switchers O
from O
second O
to O
third O
generation O
pills O
relative O
to O
switchers O
from O
third O
to O
second O
generation O
pills O
. O
[SEP] O

[CLS] O
Lidocaine B
reduced O
the O
area O
of O
punctate O
- O
evoked O
hyperalgesia O
significantly O
. O
[SEP] O

[CLS] O
The O
purpose O
of O
the O
present O
study O
was O
to O
examine O
the O
safety O
and O
efficacy O
of O
ketamine B
for O
sedation O
in O
the O
treatment O
of O
children O
' O
s O
fractures O
in O
the O
emergency O
department O
. O
[SEP] O

[CLS] O
As O
a O
result O
, O
switching O
to O
tacrolimus B
has O
been O
reported O
to O
be O
a O
viable O
therapeutic O
option O
in O
the O
setting O
of O
cyclosporine B
- O
induced O
TMA O
. O
[SEP] O

[CLS] O
Paclitaxel B
, O
cisplatin B
, O
and O
gemcitabine B
combination O
chemotherapy O
within O
a O
multidisciplinary O
therapeutic O
approach O
in O
metastatic O
nonsmall O
cell O
lung O
carcinoma O
. O
[SEP] O

[CLS] O
In O
the O
present O
paper O
the O
authors O
describe O
2 O
female O
patients O
who O
developed O
incontinence O
secondary O
to O
the O
selective O
serotonin B
reuptake O
inhibitors O
paroxetine B
and O
sertraline B
, O
as O
well O
as O
a O
third O
who O
developed O
this O
side O
effect O
on O
venlafaxine B
. O
[SEP] O

[CLS] O
Two O
mouse O
lines O
were O
selectively O
bred O
according O
to O
their O
sensitivity O
( O
BS O
line O
) O
or O
resistance O
( O
BR O
line O
) O
to O
seizures O
induced O
by O
a O
single O
i O
. O
p O
. O
injection O
of O
methyl B
beta I
- I
carboline I
- I
3 I
- I
carboxylate I
( O
beta B
- I
CCM I
) O
, O
an O
inverse O
agonist O
of O
the O
GABA B
( O
A O
) O
receptor O
benzodiazepine B
site O
. O
[SEP] O

[CLS] O
Propylthiouracil B
therapy O
was O
withdrawn O
, O
and O
she O
was O
treated O
with O
a O
1 O
- O
month O
course O
of O
prednisone B
, O
which O
alleviated O
her O
symptoms O
. O
[SEP] O

[CLS] O
GSPE B
+ O
drug O
exposed O
tissues O
exhibited O
minor O
residual O
damage O
or O
near O
total O
recovery O
. O
[SEP] O

[CLS] O
Patients O
who O
experienced O
a O
manic O
or O
hypomanic O
switch O
were O
compared O
with O
those O
who O
did O
not O
on O
several O
variables O
including O
age O
, O
sex O
, O
diagnosis O
( O
DSM O
- O
IV O
bipolar O
I O
vs O
. O
bipolar O
II O
) O
, O
number O
of O
previous O
manic O
episodes O
, O
type O
of O
antidepressant B
therapy O
used O
( O
electroconvulsive O
therapy O
vs O
. O
antidepressant B
drugs O
and O
, O
more O
particularly O
, O
selective O
serotonin B
reuptake I
inhibitors I
[ O
SSRIs B
] O
) O
, O
use O
and O
type O
of O
mood O
stabilizers O
( O
lithium B
vs O
. O
anticonvulsants O
) O
, O
and O
temperament O
of O
the O
patient O
, O
assessed O
during O
a O
normothymic O
period O
using O
the O
hyperthymia O
component O
of O
the O
Semi O
- O
structured O
Affective O
Temperament O
Interview O
. O
[SEP] O

